It is of great importance to examine whether serum IL-6 expression differs between patients with GLM and those with benign breast tumors and to explore the correlation between IL-6 and traditional inflammatory indicators, such as WBC, NRU, and CRP values, as GLM is an inflammatory disease and IL-6 is a pleiotropic cytokine. Here, CRP is linked to breast benign neoplasm.